ZyVersa Therapeutics (ZVSA) Expected to Announce Earnings on Monday

ZyVersa Therapeutics (NASDAQ:ZVSAGet Free Report) will likely be issuing its quarterly earnings data before the market opens on Monday, March 24th. Analysts expect the company to announce earnings of ($6.30) per share for the quarter.

ZyVersa Therapeutics Trading Down 1.4 %

Shares of NASDAQ:ZVSA opened at $0.79 on Monday. ZyVersa Therapeutics has a 52-week low of $0.76 and a 52-week high of $10.20. The firm has a fifty day moving average of $1.23 and a 200 day moving average of $1.58.

About ZyVersa Therapeutics

(Get Free Report)

ZyVersa Therapeutics, Inc, a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity.

See Also

Earnings History for ZyVersa Therapeutics (NASDAQ:ZVSA)

Receive News & Ratings for ZyVersa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZyVersa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.